Abstract
Background Cue reactivity is one of the most frequently used paradigms in functional magnetic resonance imaging (fMRI) studies of substance use disorders (SUDs). While there have been promising results elucidating the neurocognitive mechanisms of SUDs and SUD treatments, the interpretability and reproducibility of these studies is limited by incomplete reporting of participant characteristics, task design, craving assessment, scanning preparation and analysis decisions in fMRI drug cue reactivity (FDCR) experiments. This hampers clinical translation, not least because systematic review and meta-analysis of published work is difficult. This consensus paper and Delphi study aims to outline the important methodological aspects of FDCR research, present structured recommendations for more comprehensive methods reporting, and review the FDCR literature to assess the reporting of items that are deemed important.
Methods Fifty-five FDCR scientists from around the world participated in this study. First, an initial checklist of items deemed important in FDCR studies was developed by several members of the Enhanced NeuroImaging Genetics through Meta-Analyses (ENIGMA) Addiction working group based on a systematic review. Using a modified Delphi consensus method, all experts were asked to comment on, revise or add items to the initial checklist, and then to rate the importance of each item in subsequent rounds. The reporting status of items in the final checklist was investigated in 108 recently published FDCR studies identified through a systematic review.
Results By the final round, 38 items reached the consensus threshold and were classified under 7 major categories: “Participant Characteristics”, “General fMRI Information”, “General Task Information”, “Cue Information”, “Craving Assessment Inside Scanner”, “Craving Assessment Outside Scanner” and “Pre- and Post- Scanning Considerations”. The review of the 108 FDCR papers revealed significant gaps in the reporting of the items considered important by the experts. For instance, while items in the “general fMRI reporting” category were reported in 90.5% of the reviewed papers, items in the “pre- and post-scanning considerations” category were reported by only 44.7% of reviewed FDCR studies.
Conclusion Considering the notable and sometimes unexpected gaps in the reporting of items deemed to be important by experts in any FDCR study, the protocols could benefit from the adoption of reporting standards. This checklist, a living document to be updated as the field and its methods advance, can help improve experimental design, reporting, and the widespread understanding of the FDCR protocols. This checklist can also provide a sample for developing consensus statements for protocols in other areas of task-based fMRI.
Competing Interest Statement
Raymond F. Anton is Chair of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative (ACTIVE Group), which has received support in the past 36 months by: Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. He has been a recent consultant for Allergan, Alkermes, Dicerna, Insys, Laboratorio Pharmaceutico and Life Technologies, as well as receiving grant funding from Laboratorio Pharmaceutico. Amy C. Janes consults for Axial Biotherapeutics. Marc Potenza consulted for and advised the Addiction Policy Forum, Game Day Data, AXA, Idorsia and Opiant/Lakelight Therapeutics; received research support from the Mohegan Sun Casino and the National Center for Responsible Gaming (now the International Center for Responsible Gaming); consulted for legal and gambling entities on issues related to impulse-control and addictive disorders; given academic lectures in grand rounds, CME events, and other clinical/scientific venues; and generated books or chapters for publishers of mental health texts. Joseph P. Schacht has consulted for and received grant funding from Laboratorio Farmaceutico CT. Other authors declare no competing interests.
Funding Statement
Raymond F. Anton is supported by NIAAA P50 AA010761. Patrick Bach is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project-ID 402170461, TRR 265 (Heinz et al., Addict Biol. 2019). Anne Beck is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project-ID 402170461, TRR 265-project C02 (Heinz et al., Addict Biol. 2019). Kelly E. Courtney is supported by the California Tobacco-Related Disease Research Grant Program of the University of California grant number T30IP0962. Hamed Ekhtiari is supported by the Laureate Institute for Brain Research (LIBR), Warren K. Family Foundation, Oklahoma Center for Advancement of Science and Technologies (OCAST, #HR18-139) and Brain and Behavior Foundation (NARSAD Young Investigator Award #27305). Francesca M. Filbey is supported by the National Institute on Drug Abuse grants R01 DA030344 and R21DA044465. Rita Z. Goldstein is supported by NIDA grants R01DA041528, R01DA048301 and R01DA047851 and NCCIH grant R01AT010627. Erica Grodin is supported by the National Institute on Alcohol Abuse and Alcoholism grant F32AA027699. Andreas Heinz is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project-ID 402170461, TRR 265 (Heinz et al., Addict Biol. 2019). Amy C. Janes is supported by R01DA039135 and K02DA042987. Marc J. Kaufman is supported by R01 DA041866. Hamid R Noori is supported by the Bundesministerium fur Bildung und Forschung (e:Med program: FKZ: 01ZX1503 and 01ZX1909B), and the Deutsche Forschungsgemeinschaft (TRR 265-A05). Jason A. Oliver is supported by NIDA grant K23DA042898. Stephane Potvin is holder of Eli Lilly Canada Chair on schizophrenia research. Joseph P. Schacht is supported by NIAAA grants R01 AA027765 and R01 AA026859. Dongju Seo is supported by R01AA026844 and K08AA023545. Vaughn R. Steele is partially funded by the National Institute on Drug Abuse (NIDA) grant K12 DA000167. Susan F. Tapert is supported by NIAAA grants U01 AA021692 and U24 AA021695, and NIDA grants U01 DA041089 and U24 DA041147. Antoinio Verdejo-Garcia is supported by the Australian Medical Research Future Fund (MRF1141214). Sabine Vollstadt-Klein is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation): Project ID-402170461 (Heinz et al., Addict Biol. 2019), Project ID-421888313, Project-ID 437718741 and Project-ID 324164820. Reagan Wetherill is supported by K23AA023894, R01DA040670, and R21HL144673. Stephen J. Wilson is supported by R01DA041438 and R21DA045853. Katie Witkiewitz is supported by the National Institute on Alcohol Abuse and Alcoholism grants R01AA023665 and R01AA022328. Kai Yuan is supported by the National Natural Science Foundation of China (Grant No. 81871426). Anna Zilverstand is supported by NIDA grants P30 DA048742 and R01DA047851. The views presented in this manuscript represent those of the authors and not necessarily those of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Neither responding to the basic information collected nor commenting on and rating the checklist items was deemed to require the disclosure of personal information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Figure 1 is added for schematic representation of key reportable aspects of an fMRI drug cue reactivity study. New information is presented on the status of reporting of the checklist items among fMRI drug cue-reactivty studies published from 2017 to 2020, and the correlates of reporting status, in Figure 5.
Data Availability
The data of this project is partially available at https://osf.io/gwrh6/. Other details are available upon appropriate requests from the corresponding author.
